6/4 2021

MCDC member receives DoD funding for Phase-2 trials of PUL-042 against COVID-19

2021-07-07T19:42:22+00:00June 4th, 2021|Success Stories|

Pulmotect, Inc., a clinical-stage biotechnology company and non-traditional Medical CBRN Defense Consortium (MCDC) member, is joining the fight against COVID-19.

6/2 2021

Centivax and U.S. Naval Medical Research Center announce strategic partnership to initiate clinical development of a broad-spectrum injectable for COVID-19, with $4.2M from the Henry Jackson Foundation

2021-07-07T19:43:02+00:00June 2nd, 2021|ATI in the News|

"With discovery research supported by Medical Technology Enterprise Consortium, and now clinical development supported by our remarkable collaboration with the Naval Medical Research Center, this biotech-government partnership is proud to advance this molecule into clinical development and closer to the patients and doctors that need a better medicine to end the pandemic."

5/26 2021

MTEC member researches treatment of septic shock, the cause of 70% of COVID deaths

2021-07-07T19:50:26+00:00May 26th, 2021|Success Stories|

Vivacelle Bio, Inc., a non-traditional small business and Medical Technology Enterprise Consortium (MTEC) member, was awarded $5.3 million to research treatment of septic shock.

5/20 2021

MTEC member developing novel engineered antibody that neutralizes coronaviruses

2021-07-07T19:57:53+00:00May 20th, 2021|Success Stories|

With funding from the Medical Technology Enterprise Consortium (MTEC), Centivax is developing an optimized antibody therapeutic to treat, as well as protect against, COVID-19.

Go to Top